Aditya Birla Sun Life Pharma & Healthcare Fund Analyst Review: NAV, Returns and Key Insights 2026
- May 28, 2026
- Posted by: Kunal Singla
- Category: Uncategorized
With a 1-year return of 12.98%, the Aditya Birla Sun Life Pharma & Healthcare Fund has delivered modest gains for investors navigating the current market environment. Managing Rs 900.87 crore in assets at a NAV of Rs 37.37, the fund offers focused exposure to its target category. This review examines key data points and what investors should know before allocating capital in 2026.
Click Here – Get Mutual Fund Advisory
What Is the Aditya Birla Sun Life Pharma & Healthcare Fund?
The Aditya Birla Sun Life Pharma & Healthcare Fund is classified as a Sectoral/Thematic equity fund, investing in companies aligned with a specific sector or economic theme. The concentrated nature of such funds can drive strong outperformance when the underlying theme is in favour but can also amplify losses during sector downturns. The fund carries a Very High risk rating and should be treated as a tactical allocation rather than a core holding.
Aditya Birla Sun Life Pharma & Healthcare Fund NAV and AUM
The current NAV of the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth plan is Rs 37.37. NAV is updated each trading day and reflects the closing market prices of the fund’s underlying securities. Always verify the most recent NAV on the AMC website or a registered mutual fund platform before placing any transaction.
With an AUM of Rs 900.87 crore, the fund is relatively nimble. This can be advantageous for portfolio agility and the ability to take positions without significant market impact. Investors should track AUM trends alongside performance metrics when evaluating this fund.
Aditya Birla Sun Life Pharma & Healthcare Fund Returns: Performance Snapshot
| Period | Returns |
|---|---|
| 1 Month | 8.02% |
| 3 Months | 6.35% |
| 1 Year | 12.98% |
| 3 Years (Annualised) | 26.38% |
| 5 Years (Annualised) | 14.39% |
Return generation has been subdued for the Aditya Birla Sun Life Pharma & Healthcare Fund with a 1-year return of 12.98% and a 3-month figure of 6.35%. Investors already holding this fund should assess whether the underlying investment thesis remains intact. Those considering a new entry should evaluate the fundamental outlook and wait for a clearer performance trend before making a commitment.
Expense Ratio and Cost Efficiency
At 0.86% per annum, the expense ratio of the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth plan is moderate for its peer group. The direct plan remains more cost-efficient than the regular variant. Investors should factor the total cost of ownership into their long-term return calculations and compare across category peers before making a final decision.
Who Should Invest in Aditya Birla Sun Life Pharma & Healthcare Fund?
Investors confident in the long-term prospects of the Aditya Birla Sun Life Pharma & Healthcare Fund’s underlying investment theme can consider allocating to this fund as part of a satellite strategy. A minimum 5 to 7-year horizon and Very High risk tolerance are essential. The minimum SIP is Rs 100 and minimum lumpsum is Rs 1000. Conservative and first-time investors should avoid this fund entirely.
Key Risks to Consider
Timing Risk: Entry at peak valuations during a theme’s popularity can result in extended periods of underperformance. Thematic funds are highly sensitive to investor entry and exit timing.
Regulatory Risk: Sectors such as defence, pharma, and energy can be significantly impacted by government policy changes or regulatory shifts that are difficult to predict in advance.
Theme Obsolescence: Investment themes may lose relevance due to technological disruption, changing consumer behaviour, or structural shifts in the underlying industry.
Concentration Risk: Funds with a focused investment mandate are more vulnerable to segment-specific headwinds than broadly diversified equity schemes.
Download the Univest iOS App or Univest Android App to track this fund’s live NAV and manage your portfolio.
Conclusion
The Aditya Birla Sun Life Pharma & Healthcare Fund has delivered modest returns in a challenging environment, but its expense ratio of 0.86% and AUM of Rs 900.87 crore reflect a cost-efficient and investor-supported structure. Those already holding this fund should review the underlying investment thesis. New investors should ensure they have a sufficient horizon before committing capital. Consult a SEBI-registered investment advisor before any allocation change.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Frequently Asked Questions
What is the current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund?
Ans. The current NAV of the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth plan is Rs 37.37. NAV is updated each trading day and reflects the closing market value of the fund’s underlying holdings. Always verify the most recent NAV on the AMC website or a SEBI-registered mutual fund platform before transacting.
What are the returns of Aditya Birla Sun Life Pharma & Healthcare Fund?
Ans. The fund has delivered a 1-year return of 12.98% and a 3-month return of 6.35%. The 3-year annualised return is 26.38% and the 5-year annualised return is 14.39%. Past performance does not guarantee future results and should be evaluated alongside the fund’s risk profile and benchmark comparison.
What is the expense ratio of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?
Ans. The expense ratio of the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth plan is 0.86% per annum. The direct plan eliminates distributor commissions and is more cost-efficient than the regular plan. Investors should always opt for the direct plan to maximise long-term net returns through the compounding advantage of lower costs.
Is this fund suitable for conservative investors?
Ans. No. This fund carries a Very High risk rating due to concentrated exposure to a specific market segment or investment theme. It is not suitable for conservative investors or those with short investment timelines. A minimum 5 to 7-year horizon and a high risk tolerance are required prerequisites. Consult a SEBI-registered investment advisor before investing.
What is the minimum SIP amount for this fund?
Ans. The minimum monthly SIP is Rs 100 and the minimum lumpsum investment is Rs 1000. The low entry thresholds make the fund accessible across income levels. A regular SIP approach is recommended to average out entry costs over time, particularly given the high-volatility nature of this fund’s category.
What category and sub-category does this fund belong to?
Ans. This fund is a Sectoral/Thematic equity fund with a focused portfolio aligned to a specific sector or theme. It falls under the Sectoral / Thematic sub-category and is available as a direct growth plan, which eliminates distributor commissions and typically offers superior net returns compared to the regular plan.
